Literature DB >> 12412012

VEGF signaling is required for the assembly but not the maintenance of embryonic blood vessels.

W Scott Argraves1, Amanda C Larue, Paul A Fleming, Christopher J Drake.   

Abstract

Here we investigated the importance of vascular endothelial growth factor (VEGF) signaling to the de novo formation of embryonic blood vessels, vasculogenesis, as opposed to the maintenance of blood vessels. We found that antagonizing the activity of the VEGF signaling pathway by using soluble VEGF receptor 1 (sFlt1) or VEGF antibodies inhibited vasculogenesis that occurs in embryos and in cultures of 7.5 days postcoitus prevascular mesoderm. Antagonist treatment resulted in the formation of clusters of endothelial cells not normally observed during vasculogenesis. In contrast, when embryos with established vasculatures or cultures of vascularized mesoderm were treated with sFlt1 or VEGF antibodies, no discernible alterations to the preexisting blood vessels were observed. These observations indicate that, although VEGF signaling is required to promote the mesenchymal to epithelial transition by which angioblasts assemble into nascent endothelial tubes, it is not required by endothelial cells to maintain their organization as an endothelium. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412012     DOI: 10.1002/dvdy.10162

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  13 in total

Review 1.  How blood vessel networks are made and measured.

Authors:  John C Chappell; David M Wiley; Victoria L Bautch
Journal:  Cells Tissues Organs       Date:  2011-10-12       Impact factor: 2.481

2.  Sphingosine-1-phosphate signaling in vasculogenesis and angiogenesis.

Authors:  Kelley M Argraves; Brent A Wilkerson; W Scott Argraves
Journal:  World J Biol Chem       Date:  2010-10-26

Review 3.  The murine allantois: a model system for the study of blood vessel formation.

Authors:  Ripla Arora; Virginia E Papaioannou
Journal:  Blood       Date:  2012-07-31       Impact factor: 22.113

4.  Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.

Authors:  Ren-Yuan Bai; Verena Staedtke; Charles M Rudin; Fred Bunz; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

Review 5.  Tie-1: A potential target for anti-angiogenesis therapy.

Authors:  Ping Yang; Na Chen; Jing-Hui Jia; Xue-Jiao Gao; Shi-Han Li; Jing Cai; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

6.  Hypoxia influences the vascular expansion and differentiation of embryonic stem cell cultures through the temporal expression of vascular endothelial growth factor receptors in an ARNT-dependent manner.

Authors:  Yu Han; Shu-Zhen Kuang; Alla Gomer; Diana L Ramirez-Bergeron
Journal:  Stem Cells       Date:  2010-04       Impact factor: 6.277

7.  VEGF-mediated fusion in the generation of uniluminal vascular spheroids.

Authors:  Carmine Gentile; Paul A Fleming; Vladimir Mironov; Kelley M Argraves; W Scott Argraves; Christopher J Drake
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

8.  Expression of pro- and anti-angiogenic factors during the formation of the periocular vasculature and development of the avian cornea.

Authors:  Sam Kwiatkowski; Ravi P Munjaal; Teresa Lee; Peter Y Lwigale
Journal:  Dev Dyn       Date:  2013-04-24       Impact factor: 3.780

9.  VE-cadherin is a critical endothelial regulator of TGF-beta signalling.

Authors:  Noemi Rudini; Angelina Felici; Costanza Giampietro; MariaGrazia Lampugnani; Monica Corada; Kendra Swirsding; Massimiliano Garrè; Stefan Liebner; Michelle Letarte; Peter ten Dijke; Elisabetta Dejana
Journal:  EMBO J       Date:  2008-03-13       Impact factor: 11.598

10.  VEGF-mediated phosphorylation of eNOS regulates angioblast and embryonic endothelial cell proliferation.

Authors:  Carmine Gentile; Robin C Muise-Helmericks; Christopher J Drake
Journal:  Dev Biol       Date:  2012-10-24       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.